Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

GHSG and EORTC/GELA Early-Stage Classical Hodgkin Lymphoma Risk Groups

A strict interpreter of two historical cooperative-group definitions.

Evidence-based context for fast calculator use

Purpose:
Report the selected source group and controlling factors without selecting treatment.
Population:
Newly diagnosed, untreated classical Hodgkin lymphoma in the selected source scope.
Factors:
Stage, System-specific nodal map, Raw mediastinal and thoracic widths, ESR, B symptoms, Extranodal disease, Age
Reference:
GHSG HD10/HD11 era and EORTC/GELA H9-U.
HomeGHSG and EORTC/GELA Early-Stage Classical Hodgkin Lymphoma Risk Groups
Pin your most used calculators here by clicking the star in the dropdown.

GHSG and EORTC/GELA Early-Stage Classical Hodgkin Lymphoma Risk Groups

Choose one source system; the calculator does not merge GHSG and EORTC/GELA rules.

years

Age is an EORTC/GELA risk factor at 50 years or older and remains part of the complete baseline record for either source system.

Scope check: the selected definitions apply to classical Hodgkin lymphoma.

Scope check: these are newly diagnosed baseline group definitions.

Scope check: use pretreatment baseline data.

Required to apply the selected source population and anatomic-scope rules.

Enter a whole-number count from the map selected below; do not substitute a different nodal map.

Must match the locked source system.

mm/h

Enter the raw pretreatment value; source thresholds and equality rules differ by system and B-symptom status.

Selects the source-specific ESR threshold and affects the GHSG stage-IIB boundary.

A GHSG factor and part of the GHSG stage-IIB advanced-treatment-group boundary; retained for complete source-specific assessment.

cm

Use the raw width from the same image and level as the thoracic width; must not exceed it.

cm

Must be positive; classification uses the unrounded ratio through exact cross multiplication.

Clinical Context & Background

This route applies either GHSG HD10/HD11-era or EORTC/GELA H9-U source definitions to complete pretreatment data for newly diagnosed stage I-II classical Hodgkin lymphoma. The systems retain different nodal maps, mediastinal-ratio equalities, ESR equalities, age rules, and applicability.
The output is a historical source-specific group with controlling factors. It is not a numeric prognostic score, PET-response algorithm, treatment selector, relapse probability, or chemotherapy/radiotherapy recommendation.
Formula Logic
GHSG: any source factor yields early unfavorable/intermediate, except stage IIB with B symptoms plus large mediastinal mass or extranodal disease crosses the GHSG advanced treatment-group boundary. EORTC/GELA H9-U: any source factor yields early unfavorable.

Reference Data

SystemSource-specific factors
GHSG HD10/HD11 era3 x mediastinal mass width > intrathoracic width; extranodal disease; >=3 GHSG nodal areas; ESR >50 without B symptoms or >30 with B symptoms
EORTC/GELA H9-UMediastinal mass width >=35% of intrathoracic width; age >=50; >=4 EORTC supradiaphragmatic nodal areas; ESR >=50 without B symptoms or >=30 with B symptoms

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use GHSG and EORTC/GELA Early-Stage Classical Hodgkin Lymphoma Risk Groups when source-specific GHSG HD10/HD11-era or EORTC/GELA H9-U baseline risk-group interpretation for early-stage classical Hodgkin lymphoma.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning GHSG HD10/HD11 era through EORTC/GELA H9-U.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, stage, LDH reference range, extranodal disease, performance status, and treatment timing.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not apply a lymphoma index to a different histology or relapse setting without validation.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the lymphoma subtype and treatment setting described by the model

How to apply this result

For a representative case, verify Locked source system, Age at baseline, Ann Arbor stage, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Lymphoma hubContinue to related calculators and clinical workflow resources.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through all visible production controls across GHSG favorable, GHSG bulky unfavorable, and EORTC/GELA bulky unfavorable branches.
    • The GHSG strict greater-than one-third and EORTC/GELA greater-than-or-equal 35% mediastinal-width rules rendered correctly at and just above their exact boundaries.
    • No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/early-stage-hodgkin-lymphoma-risk-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/early-stage-hodgkin-lymphoma-risk.json.

  3. : Model identity corrected

    • Locked the route to GHSG HD10/HD11-era and EORTC/GELA H9-U definitions and removed the unversioned NCCN option.
    • Separated the two nodal maps, bulk equalities, ESR equalities, age rule, and source populations.

  4. : Inputs and scope corrected

    • Replaced favorable defaults and pre-binned bulk input with a strict 14-key baseline contract and raw mediastinal/intrathoracic widths.
    • Added stage, histology, disease status, timing, anatomic distribution, and selected nodal-map applicability gates.
    • Removed numeric coercion, factor-count score framing, probabilities, and treatment-cycle, dose, drug, radiation, or PET directives.

  5. : Full validation completed

    • 1536/1536 independent deterministic assertions passed across source identity, broad source-rule states, exact boundaries, malformed and applicability cases, cross-system disagreements, trace, UI/reset, immutability, registry, report, and no-panel checks.
    • This is software implementation verification against the locked public definitions, not prospective or independent clinical validation.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Popular Tools

Myeloma R2-ISS and IMWG Frailty PanelFebrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

Why can GHSG and EORTC/GELA disagree?

They use different nodal maps, bulk equalities, ESR equalities, age rules, and source populations. The route does not merge them.

Is the factor count a prognostic score or treatment rule?

No. It is a trace of which selected-system factors matched. It does not choose chemotherapy, radiotherapy, PET adaptation, cycle count, or dose.

Evidence-based oncology decision support. Verify with clinical guidelines.